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Identity 
Alias: Minimally differentiated acute myeloid 
leukemia 
Clinics and pathology 
Epidemiology 
Rare: 3-5% of ANLL; med age 45 years; 20% are 
children; unbalanced sex ratio in the adults: 1.6 M/1 F, 
p<0.01. 
Cytology 
Cytochemistry: negative for myeloperoxydase, positive 
for myeloid markers and negative for specific markers 
of the lymphoid or megakaryocytic lineages; 
immunophenotype: CD34+, HLA-DR+, CD117+ 
(corresponding to c-KIT), TdT+, CD7+. 
Prognosis 
Poor: CR in 50% of cases, med survival: 8 months. 
Cytogenetics 
Cytogenetics morphological 
High percentage of complex (20%) and unbalanced 
karyotypes; partial or complete monosomy (5/del(5q), -
7/del(7q), or rearrangements of chromosome 5 and/or 7 
in 15-20%; chromosome 11 rearrangements (11q23 in 
particular), and chromosome 8 involvement (+8) in 10-
15%; t(9;22)(q34;q11) in 5%; normal karyotype in 
20%. 
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